GlaxoSmithKline has announced a $500 million expanded strategic collaboration agreement with clinical stage biopharmaceutical company, Adaptimmune Therapeutics.
Adaptimmune Therapeutics specializes in the use of T-cell receptor (TCR) engineered T-cell therapy to treat cancer. GSK and Adaptimmune are partnering to push Adaptimmune’s engineered T-cell therapy — treatment that modifies a patient’s immune cells to detect and destroy cancer — into pivotal clinical trials sooner than expected.
After selling its oncology portfolio to Novartis last year, this partnership asserts GSK's continued commitment cell therapies, considered by many to be the next generation of cancer treatment.
Read the Financial Times article
